NNVC NanoViricides Inc

0.05 (3.57%)
Last Updated: 14:44:34
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 18,725
Bid Price
Ask Price
News -
Day High 1.47


52 Week Range


Day Low 1.3738
Company Name Stock Ticker Symbol Market Type
NanoViricides Inc NNVC AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.05 3.57% 1.45 14:44:34
Open Price Low Price High Price Close Price Prev Close
1.45 1.3738 1.47 1.40
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
89 18,725 $ 1.43 $ 26,812 - 1.04 - 2.00
Last Trade Time Type Quantity Stock Price Currency
14:45:07 1 $ 1.45 USD

NanoViricides Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
16.92M 11.67M - 0 -8.11M -0.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

NanoViricides News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No NNVC Message Board. Create One! See More Posts on NNVC Message Board See More Message Board Posts

Historical NNVC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.301.451.261.3019,6470.1511.54%
1 Month1.581.581.261.3621,011-0.13-8.23%
3 Months1.,1350.3329.46%
6 Months1.,1840.2116.94%
1 Year1.542.001.041.4450,535-0.09-5.84%
3 Years4.068.711.045.40561,424-2.61-64.29%
5 Years0.3819.800.160456.90708,5971.07281.58%

NanoViricides Description

Nanoviricides Inc is a nano-biopharmaceutical company which is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through an in-licensing strategy.